학술논문
盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床研究 / Clinical trial of donepezil hydrochloride tablets combined with selegiline tablets in treatment of Parkinson's disease
Document Type
Academic Journal
Source
中国临床药理学杂志 / The Chinese Journal of Clinical Pharmacology. 33(8):690-693
Subject
Language
Chinese
ISSN
1001-6821
Abstract
目的 观察盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床疗效和安全性.方法 将92例帕金森病患者随机分为对照组46例和试验组46例.对照组予以司来吉兰片每次5 mg,bid,口服;试验组在对照组治疗的基础上,予以盐酸多奈哌齐片每次5 mg,bid,口服.2组患者均治疗2个月.比较2组患者的临床疗效、帕金森病评分量表(UPDRS)、蒙特利尔认知评估量表(MoCA)和简易精神状态量表(MMSE)评分、Barthel指数、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽(GSH),以及药物不良反应的发生情况.结果 治疗后,试验组和对照组的总有效率分别为95.65％(44/46例)和76.09％(35/46例),差异有统计学意义(P＜0.05).治疗后,试验组和对照组的UPDRS评分分别为(47.03±7.21),(61.67±7.28)分;MoCA评分分别为(27.04±1.97),(20.67 ±2.15)分;MMSE评分分别为(25.63 ±3.57),(22.25 ±3.64)分;Barthel指数分别为(79.29 ±9.15),(68.43 ±9.32)分;SOD分别为(117.54±16.14),(98.43± 15.12) kU·L-1;MDA分别为(5.13±1.83),(5.96 ±2.14)μmol·L-;GSH分别为(47.66±8.57),(35.27士8.35).μmol·L-1,差异均有统计学意义(P＜0.05).2组患者的药物不良反应以口干、睡眠障碍、恶心、腹泻、食欲减退为主,试验组和对照组的药物不良反应发生率分别为32.61％和23.91％,差异无统计学意义(P＞0.05).结论 盐酸多奈哌齐片联合司来吉兰片治疗帕金森病的临床疗效显著,其能显著提高患者的认知功能、日常生活能力和精神状态,减轻氧化应激水平,且不增加药物不良反应的发生率.
Objective To observe the curative efficacy and safety of donepezil hydrochloride tablets combined with selegiline tablets in treatment of Parkinson's disease.Methods Ninety-two patients with Parkinson's disease were randomly divided into control group (46 cases) and treatment group (46 cases).Control group was given selegiline 5 mg,bid oral.Treatment group was given onepezil hydrochloride 5 mg,bid oral,on the basis of control group.Two groups were treated for 2 months.The clinical efficacy,unified parkinson disease rating scale (UPDRS),montreal cognitive assessment (MoCA),mini-mental state examination (MMSE),Barthel index (BI),superoxide dismutase (SOD),malondialdehyde (MDA) and glutathione (GSH)and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 95.65％ (44/46 cases)and 76.09％ (35/46 cases) with significant difference (P ＜ O.05).After treatment,the main indexes in treatment and control groups were compared:UPDRS were (47.03 ± 7.21),(61.67 ± 7.28) point;MoCA were (27.04 ± 1.97),(20.67 ± 2.15) point;MMSE were (25.63 ±3.57),(22.25 ±3.64)point;Barthel indexes were (79.29 ±9.15),(68.43 ±9.32) point;SOD were (117.54 ± 16.14),(98.43 ± 15.12) kU · L-1;MDA were (5.13 ± 1.83),(5.96 ± 2.14) μmol · L-1;GSH were (47.66 ± 8.57),(35.27 ± 8.35) μmol · L-1,with significant difference (P ＜ 0.05).The adverse drug reactions in two groups were dry mouth,sleep disorders,nausea,diarrhea and loss of appetite,the incidences of adverse drug reactions in treatment and control groups were 32.61％ and 23.91％,without significant difference (P ＞0.05).Conclusion Donepezil hydrochloride tablets combined with selegiline tablets has a definitive clinical efficacy in the treatment of Parkinson's disease,which can improve the cognitive function,daily life ability and mental state,reduce oxidative stress level,without increasing the incidence of drug adverse reactions.
Objective To observe the curative efficacy and safety of donepezil hydrochloride tablets combined with selegiline tablets in treatment of Parkinson's disease.Methods Ninety-two patients with Parkinson's disease were randomly divided into control group (46 cases) and treatment group (46 cases).Control group was given selegiline 5 mg,bid oral.Treatment group was given onepezil hydrochloride 5 mg,bid oral,on the basis of control group.Two groups were treated for 2 months.The clinical efficacy,unified parkinson disease rating scale (UPDRS),montreal cognitive assessment (MoCA),mini-mental state examination (MMSE),Barthel index (BI),superoxide dismutase (SOD),malondialdehyde (MDA) and glutathione (GSH)and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 95.65％ (44/46 cases)and 76.09％ (35/46 cases) with significant difference (P ＜ O.05).After treatment,the main indexes in treatment and control groups were compared:UPDRS were (47.03 ± 7.21),(61.67 ± 7.28) point;MoCA were (27.04 ± 1.97),(20.67 ± 2.15) point;MMSE were (25.63 ±3.57),(22.25 ±3.64)point;Barthel indexes were (79.29 ±9.15),(68.43 ±9.32) point;SOD were (117.54 ± 16.14),(98.43 ± 15.12) kU · L-1;MDA were (5.13 ± 1.83),(5.96 ± 2.14) μmol · L-1;GSH were (47.66 ± 8.57),(35.27 ± 8.35) μmol · L-1,with significant difference (P ＜ 0.05).The adverse drug reactions in two groups were dry mouth,sleep disorders,nausea,diarrhea and loss of appetite,the incidences of adverse drug reactions in treatment and control groups were 32.61％ and 23.91％,without significant difference (P ＞0.05).Conclusion Donepezil hydrochloride tablets combined with selegiline tablets has a definitive clinical efficacy in the treatment of Parkinson's disease,which can improve the cognitive function,daily life ability and mental state,reduce oxidative stress level,without increasing the incidence of drug adverse reactions.